^
Association details:
Biomarker:IDH1 R132H
Cancer:Glioma
Drug:AGI-5198 (IDH1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

Excerpt:
Measurements of R-2HG concentrations in pellets of TS603 glioma cells demonstrated dose-dependent inhibition of the mutant IDH1 enzyme by AGI-5198 (Fig. 1D). When added to TS603 glioma cells growing in soft agar, AGI-5198 inhibited colony formation by 40 to 60%...examined the effects of orally administered AGI-5198 on the growth of human glioma xenografts. When given daily to mice with established R132H-IDH1 glioma xenografts, AGI-5198 [450 mg per kg of weight (mg/kg) per os] caused 50 to 60% growth inhibition (Fig. 2A). Treatment was tolerated well with no signs of toxicity during 3 weeks of daily treatment (fig. S3).
DOI:
10.1126/science.1236062